Press Releases 2019

All     |     2019     |     2018     |     2017

State-of-the-art manufacturing facility will support clinical and commercial production of cell therapies for thousands of patients annually worldwide.

Tessa will establish a joint venture with China-Singapore Guangzhou Knowledge City (CSGKC). The joint venture will be the sole licensee of Tessa’s cell therapies for research, clinical development and commercialization in China.

Tessa Therapeutics today announced ‘proof-of-concept’ data from the preclinical study of TT16, a first-of-its-kind combination immunotherapy that integrates Chimeric Antigen Receptor (CAR) T cell therapy and oncolytic adenovirus expressing immunomodulatory molecules for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-positive solid tumors.

The collaboration will evaluate the safety and efficacy of Tessa’s armored human papillomavirus-specific T cell (HPVST) therapy combined with MSD’s KEYTRUDA® (pembrolizumab) to address the limited number of effective treatment options for metastatic or recurrent cervical cancer

Mr Buchalter brings over thirty years’ experience in the biopharmaceutical industry, with strong corporate leadership and an extensive background in the commercial positioning and development of therapeutics in oncology.